Starting from a series of 928 cases that included also not de novo DLBCL and that were analyzed with a targeted panel of 293 genes, the last classification identifies five subgroups, with names based on their most common lesion (MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2), leaving 27% of cases unclassified (54) (Table 3). This evidence concerns the gene NOTCH2 and diffuse large B-cell lymphoma.